The QualityStocks Daily Monday, July 2nd, 2018

Today's Top 3 Investment Newsletters

StockMarketWatch (RSYS) +120.28%

Buzz Stocks (GBR) +110.90%

QualityStocks (VISM) +91.84%

The QualityStocks Daily Stock List

Micromem Technologies, Inc. (MMTIF)

SmallCapVoice, Xtremepicks, OurHotStockPicks, Stock Stars, and PennyStocks24 reported earlier on Micromem Technologies, Inc. (MMTIF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. is a leader in viable Sensor Technology and MRAM (Magnetoresistive Random Access Memory). Currently, the Company is centered on magnetic sensor applications through its wholly-owned subsidiary, Micromem Applied Sensor Technologies, Inc. (MAST, Inc.). Micromem Technologies is headquartered in Toronto, Ontario. The MAST, Inc. subsidiary is based in New York, New York.

Micromem’s technologies and solutions include surface functionalization of magnetic nanoparticles; nanoparticle detection platforms to sub-ppb detection levels; customized integration of NEMS/MEMS sensor platforms; magnetic sensor solutions; and sensor-based analytical solution platforms.

Technologies and solutions also include structural integrity sensors; wireless suib-surface power solutions; asset protection sensor platforms; and energy storage solutions. The Company designs, develops and provides sensors specific to industry needs.

The MAST subsidiary focuses on developing and marketing the delivery of innovative magnetic sensor applications in industries including Defense, Life Sciences, Automotive, Consumer, and Mining. MAST develops MEMS/NEMS solutions through combining disparate sensor modalities to create solutions for clients’ problems.

MAST is not a product company. MAST works closely with its clients during development to ensure a smooth transfer to their production facility. Concerning its Magnetic Nanoparticle Detection Platform, MAST, working with a leader in the oil industry, has developed an instrument that detects breakthrough water in production oil wells via magnetic and optical sensor techniques.

Regarding Energy Storage Solutions, MAST, working together with an energy storage company and a foremost U.S. utility, is providing sensor technology and overall system and product integration management for the practical realization of a new energy storage system. The system will enable lower costs than building new power generating plants.

In late May, Micromem Technologies, via its wholly-owned subsidiary Micromem Applied Sensor Technologies (MAST), reported that with its development partner, a major multi-national energy corporation, all results from testing on the MAST ATRA-171 tracer detection platform are in.

Results indicated the simultaneous detection of numerous tracer chemicals in a range of 3 orders of detection measurement and a lower limit approaching 5 parts per trillion. The Company has also received a contract payment of $510,000 US, with an additional payment of $175,000 US currently due to the Company.

The first field installation for the ATRA-171 is scheduled for next month. The ATRA-171 will be installed in an operating production environment during scheduled chemical tracer surveillance activities.

Micromem Technologies, Inc. (MMTIF), closed Monday's trading session at $0.10, up 11.11%, on 68,100 volume with 11 trades. The average volume for the last 60 days is 64,623 and the stock's 52-week low/high is $0.0723/$0.2802.


TheMaven, Inc. (MVEN)

InvestorsHub and Stockhouse reported on TheMaven, Inc. (MVEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TheMaven, Inc. is an expert-driven, group media network. Its advanced platform serves, by invitation-only, an alliance of professional, independent channel partners. TheMaven’s Executive team and operational Board members include digital media pioneers Mr. James Heckman and Mr. Ross Levinsohn, and technology innovators Mr. Bill Sornsin and Mr. Ben Joldersma. A digital media start-up, TheMaven is based in Seattle, Washington.

Maven provides elite content leaders an end-to-end digital platform within a cooperative that shares resources and distribution and maximizes monetization. Maven enables partners to focus on the essential drivers of their businesses - creating, informing, sharing, discovering, leading, and interacting with the communities and constituencies they serve. The Company enables partners to do so through providing broader distribution, more community engagement, and efficient advertising and membership programs.

Maven announced in January of this year that it agreed to acquire HubPages in a union that brings together greater than 40 million monthly unique users in a single premium digital media network, the two companies announced after signing a Letter of Intent (LOI).

HubPages’ network will undergo migration to Maven’s publishing and community platform, relaunched as part of a single premium network, on one platform for advertisers. The expectation is that moving the network to Maven will improve traffic, engagement, and monetization. HubPages will remain a vital “cultivating” network, at

Maven is partnering with to provide Maven’s content creators protection from improper use of their content and ensure fair monetization. is a blockchain-based open universal ledger for digital creative assets. will provide Maven publishers with the ability to timestamp and validate their content and digital assets in an unchangeable system, which will automatically issue digital ownership certificates.

In late March of this year, Maven announced it signed a Letter of Intent (LOI) to acquire Say Media as part of a three-way fusion, along with HubPages, which will bring together former competitors to create a dominant platform for professional, independent publishers. Maven, Say Media, and HubPages will continue to trade under the MVEN ticker symbol.

Furthermore, Maven is adding team-sports “franchises” to its extensive coalition of elite independent publishers (mavens). It is doing so through re-launching a business model its Founders invented more than two decades ago at

Maven is partnering with The Sports Xchange (TSX) to implement a nationwide, professional network of sports journalists. These journalists will provide authentic, on-the-ground content, analysis and community engagement for fans of every professional and major college team in North America.

TheMaven, Inc. (MVEN), closed Monday's trading session at $1.30, up 8.33%, on 1,928 volume with 3 trades. The average volume for the last 60 days is 11,809 and the stock's 52-week low/high is $1.00/$2.573.


MannKind Corporation (MNKD)

InvestorsHub, MarketWatch, and Stockhouse reported on MannKind Corporation (MNKD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MannKind Corporation concentrates on the development and commercialization of inhaled therapeutic products. These products are for patients with diseases such as pulmonary arterial hypertension and diabetes. The Company also employs field sales and medical representatives throughout the United States. MannKind has its head office in Westlake Village, California. It also has a state-of-the art manufacturing facility in Danbury, Connecticut.

A biopharmaceutical enterprise, MannKind is now commercializing Afrezza® (insulin human) inhalation powder. This is its first Food and Drug Administration (FDA)-approved product. Afrezza® is the only inhaled rapid-acting mealtime insulin in the United States. It is available in the U.S. by prescription from pharmacies across the country.

Afrezza® uses MannKind’s proprietary Technosphere® formulation technology. The basis of this technology is on a class of organic molecules designed to self-assemble into small particles onto which drug molecules can be loaded.

Afrezza® is available via prescription only. It is a fast-acting inhaled insulin used to improve glycemic control in adults with diabetes. MannKind’s single-use and reusable Inhalers are breath-powered. Therefore, they require only the patient’s inhalation effort to deliver the powder.

Afrezza® is taken at the beginning of a meal using the specially designed inhaler. One breath delivers one dose. MannKind’s inhalers efficiently focus the energy supplied by the patient’s breath directly onto the dry powder. This results in high delivery performance.

Afrezza® dissolves rapidly upon inhalation to the deep lung. It delivers insulin quickly to the bloodstream. Peak insulin levels are attained within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.

MannKind’s dry powder formulations are based on FDA-approved excipients. This includes fumaryl diketopiperazine (the excipient used in Technosphere® inhalation powders) and mannitol. The Company’s pipeline includes Epinephrine Technosphere® for anaphylaxis; and Treprostinil Technosphere® for Pulmonary Arterial Hypertension (PAH).  Additionally, its pipeline includes Palonosetron Technosphere® for Chemotherapy-Induced Nausea and Vomiting (CINV).

Recently, MannKind announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released June 23, 2018 at the American Diabetes Association’s 78th Scientific Sessions, which took place June 22-26, 2018, in Orlando, Florida.

The STAT study involved 60 patients with Type 1 diabetes. It is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza. The dual primary endpoints were assessment of glucose time-in-range and postprandial glucose (PPG) excursions in the 1-4-hour post-meal period.

Mr.  David Kendall, M.D., Chief Medical Officer of MannKind Corporation, stated, “We are very pleased to present results of the novel STAT trial. This is the first time we have seen a rapid-acting mealtime insulin provide a superior outcome when utilized with CGM in a treat-to-target dosing strategy. The results demonstrated that Afrezza dosed before and (as needed) after meals significantly improved all-day glucose time-in-range, limited daytime glucose variability and significantly reduced the overall rate and time spent in hypoglycemia.”

MannKind Corporation (MNKD), closed Monday's trading session at $1.90, even for the day, on 995,772 volume with 3,236 trades. The average volume for the last 60 days is 2,401,483 and the stock's 52-week low/high is $1.085/$6.96.


Lexington Biosciences, Inc. (LXGTF)

MarketWatch, Tech Stock Insider, and InvestorsHub reported on Lexington Biosciences, Inc. (LXGTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lexington Biosciences, Inc. is developing the HeartSentry. This is a new non-invasive diagnostic device to measure and monitor cardiovascular health through assessing the function of a person's vascular endothelium. This is the vital innermost lining of a person's cardiovascular system. The Company’s goal is to become a leader in the development of clinical grade cardiovascular self-measurement solutions for home and clinical use.

A medical device company, Lexington Biosciences has offices in Vancouver, British Columbia; and Reno, Nevada. The Company is engaged with the US FDA (Food and Drug Administration) and other regulatory agencies on the required product approvals for the HeartSentry.   

HeartSentry targets the fast-growing self-measurement medical device sector. The design of the HeartSentry unit is to use Bluetooth and Cloud technology to provide up-to-date and accurate readings of an individual’s complete cardiovascular health through electronic monitoring for risk-assessment and treatment effectiveness targeting the prevention of heart attack and stroke.

HeartSentry is the Company’s flagship, and first device now advancing to commercial deployment. The HeartSentry core technology underwent development at the University of California Berkeley over a fifteen-year research and development (R&D) period involving numerous research studies and product iterations resulting in a portfolio of manifold pending and issued patents licensed to Lexington Biosciences.

In late 2017, the Company announced the engagement of San Francisco Bay Area-based Diablo Clinical Research to conduct its HeartSentry pilot clinical studies. The design of the clinical studies is to measure the safety and effectiveness of the HeartSentry technology for cardiovascular health diagnosis.

In May, Lexington Biosciences advised it engaged with a dedicated research team at The University of British Columbia (UBC) to perform an independent analysis and validation of the investigative data generated during the Company’s clinical study in California. UBC is an international center for research and teaching, consistently ranked among the top 20 public universities globally.

Last week, Lexington Biosciences announced the completion of the initial HeartSentry study conducted at San Francisco Bay-area Diablo Clinical Research.

Mr. Eric Willis, Lexington Biosciences’ Chief Executive Officer, said, “We are pleased with the performance of the HeartSentry device to-date. We are looking forward to the next phase of our clinical study which will provide the larger demographic and diagnosis-specific data points required for FDA submission. Once again, we find ourselves moving ahead at an excellent pace as we move towards our clinical goals.”

Fundamentally, Lexington Biosciences’ goal is to make HeartSentry accurate, fast, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person's cardiovascular health.

Lexington Biosciences, Inc. (LXGTF), closed Monday's trading session at $0.19, down 1.04%, on 66,630 volume with 27 trades. The average volume for the last 60 days is 220,762 and the stock's 52-week low/high is $0.1401/$0.4844.


Electra Meccanica Vehicles Corp. (ECCTF)

OTC Markets, Streetwise Reports, Zacks, MarketWatch, Stockhouse, Barchart, and Business Insider reported on Electra Meccanica Vehicles Corp. (ECCTF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Electra Meccanica Vehicles Corp. is a designer and manufacturer of electric vehicles. The Company is developing clean, sustainable, and renewable transportation solutions that help fight carbon pollution and climate change. Electra Meccanica has its subsidiary Intermeccanica. With it, it is delivering next generation affordable electric vehicles to the masses. OTCQB-listed, Electra Meccanica Vehicles has its corporate office in Vancouver, British Columbia.

The Company is being built in collaboration with world-renowned coach builder, Intermeccanica. For 59 years Intermeccanica has successfully been building high-end specialty cars. Essentially, Electra Meccanica Vehicles combines Founder Jerry Kroll’s extensive background in the race car industry with Henry Reisner’s Intermeccanica Custom Coach Builders’ 50 years of experience in building high-quality, specialty vehicles.

Electra Meccanica builds the innovative, all-electric SOLO. This is a single passenger vehicle. It underwent development to transform the way in which people commute. In addition, Electra Meccanica builds the Tofino convertible. This is an elegant high-performance sports car.

The basis for the SOLO and future line of vehicles is the aerospace composite chassis platform. Patents are filed for the Modular Rolling Chassis, the overall SOLO shape, and other innovations.

The SOLO charging system/time is Dual 220/110 V – 3/6 hours charging time. The performance is 130 km/h top speed 0-100 km/h in 8.0 seconds.

The SOLO drivetrain is a high performance electric rear drive motor (up to 82 hp and 128 Nm torque). The battery system/range is 16.1 kW/h Lithium-Ion - up to a 160 km range. The storage capacity is 245 Liters/40 liters – rear/front storage.

Last week, Electra Meccanica Vehicles announced that its single-passenger, all-electric SOLO continues to go through laboratory safety testing to meet international safety standards. The Company received its Federal Certification in the United States earlier this year. It is currently moving ahead with continuing testing for compliance in countries worldwide.

Today, Electra Meccanica Vehicles announced that the SOLO made its debut on the New York Tri-State news service, News 12. The segment initially aired on June 29, 2018. It can be streamed in its entirety online, with more features available on Facebook. This includes a segment with News 12 personalities driving the SOLO, and a Chopper 12 Feature.

Electra Meccanica Vehicles Corp. (ECCTF), closed Monday's trading session at $6.20, even for the day. The average volume for the last 60 days is 183 and the stock's 52-week low/high is $1.50/$8.25.


Solis Tek, Inc. (SLTK)

Trading View, Zacks, and MarketWatch reported on Solis Tek, Inc. (SLTK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Solis Tek, Inc. is a vertically integrated technology innovator, developer, manufacturer, and distributor. Its emphasis is on bringing products and solutions to commercial cannabis growers in legal markets across the United States. The OTCQB-listed Company’s focus is on the research, design, development, and manufacturing of advanced and efficient lighting products. Its customers include retail stores, distributors, and commercial growers in the United States and globally. Solis Tek has its corporate headquarters in Carson, California.

The Company provides a wide-ranging line of lighting equipment and accessories to help its customers attain higher yields and maximize quality. Solis Tek product categories include complete systems; digital ballasts, DE Lamps; SE Lamps; CMH Lamps; Reflectors; and accessories.

Solis Tek’s technology encompasses Ignition Control; SenseSmart™, and the industry’s lowest output THD (Total Harmonic Distortion) percent. The Company states that its ballasts offer the industry's only true Ignition Control staggered ignition technology. Solis Tek's sequential lamp ignition technology will ignite lamps one at a time based on load stability.

The Company’s SenseSmart™ will check for eight different factors before attempting to power the lamp. The intention of this is increased user safety. SenseSmart™ checks for open output; high/low temperatures; ignition failure; thermal; end of lamp life; overflow current; over/low voltage; and short circuit.

Solis Tek has its Nutrient Line. This Line utilizes natural ingredients to help growers increase yield, lower costs, and ultimately grow healthier plants. This an aspect of the Company’s overall strategy to provide a broad group of products and services targeted at the commercial cannabis industry.

Terpenez™ is the first product in the Nutrient Line. This product is an organically derived, commercial grade essential oil intensifier blended in the State of California.

The design of it is to naturally increase the terpene profile of the cannabis plant and enhance the aromatic experience associated with gardening. Terpenez™ identifies the plant's terpene profile. It utilizes natural ingredients to boost the terpene levels, accordingly enhancing the plant's innate characteristics.

Solis Tek announced this past summer that controlled third-party independent testing efforts yielded results revealing no heavy metals in Terpenez™. A & L Western Agricultural Laboratories, Inc. conducted the laboratory analysis of Terpenez. The focus of the analysis was to ensure product safety and efficacy. The laboratory analysis determined the level of heavy metals in Terpenez to be below the EPA's (Environmental Protection Agency) detection limit (BDL). A & L Western Agricultural Laboratories is an independent bioanalytical testing and research laboratory. It provides services to the agriculture industry

Recently, Solis Tek announced the availability of its lighting controller that enables commercial growers to harness more control of its garden's lighting environment. The Solis Tek Controller works with up to 300 lights at once. It permits growers to manage multiple lighting cycles, located in different rooms/locations.

Solis Tek, Inc. (SLTK), closed Monday's trading session at $0.73, up 15.87%, on 72,467 volume with 31 trades. The average volume for the last 60 days is 67,867 and the stock's 52-week low/high is $0.57/$2.64.


Bone Biologics Corporation (BBLG)

OTC Markets, The Street, GuruFocus, StreetInsider, MarketWatch,, 4-Traders, BusinessWire, Simply Wall St, YCharts, Market Exclusive, and MarketsandMarkets reported on Bone Biologics Corporation (BBLG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Bone Biologics Corporation focuses on developing and marketing orthobiologic products. Its proprietary platform technology is NELL-1. This is a recombinant human protein growth factor essential for normal bone development. Currently, the Company is concentrating its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. Bone Biologics is based in Burlington, Massachusetts. The Company lists on the OTC Markets Group’s OTCQB.

In 2004, Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering established Bone Biologics.

Bone Biologics’ mission is to use the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. The Company’s lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the fast growing orthobiologics market.

NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as demonstrated in the lab and through the use of animal testing. NELL-1 is a recombinant human protein growth factor.

NELL-1 has the same functionality as the endogenous NELL that is vital for normal bone development. Bone Biologics’ commitment is to explore additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

Bone Biologics announced in August of 2017, that it expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NELL-1. It also entered into an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents for the worldwide application of the NELL-1 protein for osteoporosis and trauma through a technology transfer.

Bone Biologics announced in December of 2017 that it completed a preclinical study. The study shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. Additionally, rhNELL-1 was shown to be well tolerated. Moreover, there were no findings of inflammation.

In late March of this year, Bone Biologics announced the completion of $500,000 funding with Orthofix Holding, Inc. This funding represents the second round of an earlier announced private placement.

Bone Biologics Corporation (BBLG), closed Monday's trading session at $2.50, up 25.00%, on 100 volume with 1 trade. The average volume for the last 60 days is 603 and the stock's 52-week low/high is $0.51/$5.90.


Vitality Biopharma, Inc. (VBIO)

Stock Beast, SmallCap Network, and Promotion Stock Secrets reported previously on Vitality Biopharma, Inc. (VBIO), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Vitality Biopharma, Inc.’s commitment is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, it has developed a unique capability to produce molecules via glycosylation, a form of enzymatic biosynthesis that was originally developed to improve the taste of stevia. The platform is well suited for the discovery of new pharmaceutical products. OTCQB-listed, Vitality Biopharma is based in Los Angeles, California.

Late in 2015, Vitality successfully modified cannabidiol (CBD), which is not psychoactive, and in ongoing work has created a novel class of pharmaceuticals named cannabosides. Cannabosides, upon ingestion, can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while lessening or avoiding the systemic delivery of THC into the bloodstream.

Vitality Biopharma completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. The Company has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be lessened or eliminated.

The Company can biosynthesize cannabinoid glycosides (cannabosides) through enzyme biosynthesis. Vitality is one of only a very few groups internationally who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of stevia (steviol glycosides).

Vitality Biopharma announced earlier this year that it has positive results indicating a new use for its proprietary prodrug cannabinoid delivery platform. Many colon cancer cell types were screened, each with unique combinations of genetic mutations that drive cancerous growth, and including a cell line known to express drug-resistance genes such as PD-L1.

Vitality Biopharma found that cannabidiol (CBD) universally inhibited cell growth at concentrations similar to established chemotherapeutics. It also found that its cannabidiol prodrug was not toxic to the human cells at the concentrations tested, demonstrating the relative safety of its prodrug delivery system.

Vitality Biopharma has obtained positive results demonstrating antimicrobial activity of cannabinoids. It filed for patent protection on the use of cannabinoid compounds for the treatment of microbes. This includes Clostridium difficile and other "superbug" pathogens.

In July, Vitality Biopharma announced positive preclinical efficacy results for its gut-targeted cannabosides in the treatment of colitis. The Company has developed a new class of cannabinoid prodrugs, called cannabosides that upon ingestion can be targeted and limited to the gastrointestinal tract thus avoiding drug psychoactivity and unforeseen side effects. In a preclinical model of inflammatory bowel disease (IBD), cannabosides were able to decrease weight loss, lessen damage to the colon, and noticeably improve gastrointestinal health versus the placebo controls.

Last month, Vitality Biopharma announced the attainment of a biosynthesis breakthrough. The Company has developed a proprietary biosynthesis technology, which can modify cannabinoids to create pharmaceutical prodrugs that have no psychoactivity and that can provide targeted disease treatment. The process involves small molecule glycosylation, where sugar molecules are attached to cannabinoids, creating new compounds called cannabinoid glycosides, or cannabosides.

Vitality Biopharma announced in October the publication of a global PCT patent application that encompasses a new class of cannabinoid pharmaceuticals. The publication of the international patent filing is the first public disclosure of its full content. This includes 79 patent claims and close to 200 individual compounds. Furthermore, Vitality has filed for intellectual property (IP) coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders employing cannabinoids.

Vitality Biopharma, Inc. (VBIO), closed Monday's trading session at $1.90, up 4.97%, on 201,508 volume with 299 trades. The average volume for the last 60 days is 108,694 and the stock's 52-week low/high is $1.05/$2.37.


CytoDyn, Inc. (CYDY)

OTCtipReporter, SeeThruEquity Research, Stock News Now,, StockOodles, PennyStockScholar, Profitable Trader Authority, and AllPennyStocks reported previously on CytoDyn, Inc. (CYDY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biotechnology company, CytoDyn, Inc. is concentrating on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection: PRO 140. This mAb is its novel self-injectable antibody for the treatment of HIV. PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in humans and is now in Phase 3. CytoDyn has its corporate office in Vancouver, Washington.

PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells. PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors. The intention of these is to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results so far indicate that it does not affect the normal function of the cell.

Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can considerably lessen viral burden in people infected with HIV. A Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn’s goal is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. In addition, PRO 140 has been designated a "fast track" product candidate by the Food and Drug Administration (FDA).

CytoDyn’s completed Phase 2b treatment substitution trial demonstrated that 98 percent of all patients treated with PRO 140 successfully passed four weeks of monotherapy without virologic failure. The Company said that its research data has expanded the potential clinical indications for PRO 140 to include certain inflammatory diseases, autoimmunity, transplantation, as well as cancer.

Recently, CytoDyn announced that the FDA granted Orphan Drug Designation (ODD) to PRO 140 for the prevention of graft versus host disease (GvHD).  Orphan Drug Designation is granted to development-stage drugs that have shown promise in addressing serious medical needs for patients living with rare conditions.

The designation provides CytoDyn with various incentives and benefits. This includes seven years of U.S. market exclusivity for PRO 140 in GvHD, subject to FDA approval for use in this indication.

CytoDyn also announced that in a meeting, which took place October 12, 2017, the FDA confirmed the number and type of evaluable patients required for submission of a Biologics License Application (BLA) for PRO 140 as a combination therapy. The FDA accepted the 40 patients presently enrolled in the Company’s Phase 2b/3 pivotal combination trial as evaluable.

Also, the FDA further agreed that the trial’s Data Monitoring Committee can conduct an interim efficacy analysis of primary endpoint. Furthermore, the FDA confirmed that 50 patients will be required for the completion of this trial. It agreed to allow more flexibility in the enrolment criteria for the remaining 10 patients. Therefore, CytoDyn expects to complete enrolment soon.

CytoDyn, Inc. (CYDY), closed Monday's trading session at $0.485, up 3.21%, on 170,004 volume with 30 trades. The average volume for the last 60 days is 295,694 and the stock's 52-week low/high is $0.413/$0.836.


Jones Soda Co. (JSDA)

Stock Analyzer, SuperNova Elite, Wealthpire Inc., Investor Update, SmallCapVoice, Actual Gains,, PricelessPennyStocks, SmarTrend Newsletters, TopStockAnalysts, and Dividend Opportunities reported earlier on Jones Soda Co. (JSDA), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Jones Soda Co. is a leader in the premium soda category. It has a reputation for its unique flavors and branding. Jones Soda markets and distributes premium beverages under the Jones® Soda, Jones Zilch®, Jones Stripped™ and Lemoncocco™ brands. Jones Soda sells across North America in glass bottles, cans and on fountain by way of traditional beverage outlets, restaurants, and alternative accounts. Jones Soda is based in Seattle, Washington.

Jones Soda is made with pure cane sugar. The Company’s diverse product line includes pure cane sugar soda, zero-calorie soda, and an all-naturally sweetened sparkling beverage with only 30 calories and 8 grams of sugar. Jones Soda also sells Jones Gear (clothing items) and Jones Candy.

Jones Soda has its natural soda line - Jones Stripped. Natural Jones Soda launched in California during 2013 to meet the growing demand for healthier beverage options and to expand the Jones product portfolio. Jones Stripped is sweetened with a blend of natural sweeteners. These include pure cane sugar, organic agave syrup, and stevia.

7-Eleven, Inc. and Jones Soda have partnered and created 7-Select® brand premium sodas crafted by Jones, the first premium carbonated beverage in the 7-Select private brand lineup. Each 7-Select premium soda is made with natural flavors, lightly sweetened with cane sugar, and ranges from only 180 to 195 calories per 20-ounce bottle. In addition, this brand includes 75 mg. of caffeine in each serving.

Jones Beverages International is a subsidiary of Jones Soda. It has its premium non-carbonated blended beverage brand - Lemoncocco™. This product is flavored with the extracts of Sicilian lemons and a bit of coconut cream. Lemoncocco™ is a natural beverage, lightly sweetened with a little cane sugar. It is 90 calories per 12 ounce serving, and is dairy free and gluten free.

Last week, Jones Soda announced results for Q3 ended September 30, 2017. For Q3 2017, it reported Revenue of $3.6 million, versus the prior year’s Q3 Revenue of $4.1 million. The Company reported a Net Loss for Q3 of 2017 of $211,000 or ($0.01) per share, versus a Net Income of $69,000 or $0.00 per share, for Q3 2016.

Ms. Jennifer L. Cue, Jones Soda’s Chief Executive Officer, said,  “While we have had a challenging year due primarily to the loss of our Jones 12-ounce can listing, we are very excited by the growth of two of our newer initiatives, Lemoncocco and our Jones Cane Sugar fountain program. During 2017, we have added over 1,000 new retail doors for Lemoncocco including 2 divisions of Whole Foods as well as Safeway NorCal, Raley’s and the Mariano’s grocery chain in Chicago. Lemoncocco represents the Company’s diversification into lower calorie, natural beverages, to better meet changing consumer beverage trends. Equally exciting, our Fountain revenue grew by 200 percent for the nine month period as we continue to land increasingly larger sized quick service restaurants and accounts.”

Jones Soda Co. (JSDA), closed Monday's trading session at $0.2823, up 1.91%, on 13,875 volume with 10 trades. The average volume for the last 60 days is 45,109 and the stock's 52-week low/high is $0.2511/$0.52.


Q BioMed, Inc. (QBIO)

StockPicksNYC, Stock News Now, and SeeThruEquityResearch reported on Q BioMed, Inc. (QBIO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biomedical acceleration and development company based in New York City. The Company’s commitment is on licensing and acquiring biomedical assets across the healthcare spectrum. The Company formerly went by the name ISMO Tech Solutions, Inc. It changed its name to Q BioMed, Inc. in July of 2015. Q BioMed’s shares trade on the OTC Markets’ OTCQB.

Q BioMed’s dedication is to provide these target assets the strategic resources, developmental support, as well as expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. The Company’s corporate mission is to license and acquire pioneering life sciences assets from academia or small private companies.

The Company is concentrating on clinical stage and innovative products where the technical, regulatory, and commercial risks have been lessened or major valuation inflections are pending. It has numerous assets across a broad assortment of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies.

Q BioMed is also developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of IOP (Intraocular Pressure) - one of the main causes of glaucoma. The platform is innovative and first-in-class. Q BioMed, together with its partner, Mannin Research, Inc., is the only company targeting this mechanism of action.

Q BioMed has commenced production of Strontium-89 Chloride. This is a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be utilized in combination with, or to decrease the need for opiate based drugs, as well as in combination with cancer therapeutic drugs.

Q BioMed has entered into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). With the agreement, the Company has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.

In September, Q BioMed announced a partnership with Sphaera Pharma. This is to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. Sphaera Pharma will utilize its proprietary and patented platform to produce a novel analog, which aims to lessen or eliminate potential side effects and can decrease the amount of product a toddler needs to take on a daily basis.

Last month, Q BioMed announced the launch of The design of this website is to provide a resource for patients, doctors, and caregivers dealing with the severe pain associated with late stage cancer metastases to the bone.

Q BioMed, Inc. (QBIO), closed Monday's trading session at $3.44, up 1.18%, on 31,040 volume with 113 trades. The average volume for the last 60 days is 83,402 and the stock's 52-week low/high is $2.73/$5.90.


MedMen Enterprises, Inc. (MMNFF)

OTC Markets, Penny Stock Hub, OTC Stock Watch, Stockhouse, 4-Traders, Morningstar, Insider Financial, MarketWatch, Daily Marijuana Observer, Investors Hangout, The Street, Wallmine, TradingView, Barchart, Stockwatch, OTC Stock Picks, New Cannabis Ventures, Investing News, and GuruFocus reported on MedMen Enterprises, Inc. (MMNFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MedMen Enterprises, Inc. brings expertise and capital to the cannabis industry. The Company is one of the nation’s largest financial supporters of progressive marijuana laws. MedMen Enterprises owns and operates 18 facilities encompassing the entire vertical from cultivation to manufacturing to retail in three key states - California, Nevada and New York.

The Company has its corporate headquarters in Los Angeles, California. On May 29, 2018, MedMen Enterprises became a publicly traded company by way of a reverse takeover, or RTO. The Company’s shares trade on the OTC Markets Group’s OTCQB. MedMen enterprises has more than 800 employees.

MedMen’s professional team consists of cannabis experts, retail experts, marketing experts, financing experts, regulatory affairs experts, and agricultural and operations experts. The Company manages class leading retail stores that sell marijuana and marijuana products.

MedMen Enterprises operates a number of dispensaries in the most strategic markets in the nation. It has a fast-growing footprint that includes expansion plans in other important states as well as Canada.

Recently, MedMen Enterprises announced that it added ground cannabis flower to its product offerings in the State of New York. At present, MedMen stores in New York offer vaporizer pens, tinctures and gel caps in five different formulations. The addition of ground flower will give the Company’s New York medical marijuana patients more product choices in the State’s fast developing market.

Last week, MedMen Enterprises announced the upcoming opening of its marquee location in the heart of Downtown Las Vegas, Nevada. MedMen Enterprises has a total of three stores now planned for Las Vegas. This includes one on Paradise Road, near the Hard Rock Hotel and the Las Vegas International Airport, which won county approval recently.

MedMen Enterprises recently announced its expansion into a fourth key market, Florida, via a proposed acquisition of dispensary and cultivation assets from Treadwell Simpson Partnership and affiliates.

MedMen Enterprises, Inc. (MMNFF), closed Monday's trading session at $3.77, up 13.55%, on 249,259 volume with 316 trades. The average volume for the last 60 days is 161,110 and the stock's 52-week low/high is $2.61/$4.99.


The QualityStocks Company Corner

Hunter Oil Corp. (TSX-V: HOC) (OTCQX: HOILF)

The QualityStocks Daily Newsletter would like to spotlight Hunter Oil Corp. (HOILF).

Hunter Oil (TSX.V: HOC) (OTCQX: HOILF) is engaged in acquisition, development, operation, and exploitation of crude oil and natural gas properties in the Permian Basin in eastern New Mexico. To view the full article, visit:

Hunter Oil Corp. (TSX-V: HOC) (OTCQX: HOILF) (“Hunter Oil” or the “Company”) is an oil and gas exploration, development and production company. The Company’s corporate headquarters are located in Vancouver, British Columbia, and its operational headquarters are in Houston, Texas. Along with its subsidiaries, Hunter Oil is engaged in acquisition, development, operation, and exploitation of crude oil and natural gas properties in the Permian Basin in eastern New Mexico. The Company owns and operates two large, proven oil fields – the Chaveroo and Milnesand San Andres fields – with a total acreage position of over 23,000 acres that are essentially contiguous. Hunter Oil’s operations involve re-accessing the existing reservoirs and developing the resource by utilizing contemporary completion techniques and proven unconventional recovery technologies.

First developed in the 1950s and 1960s using vertical well production technology, the Chaveroo and Milnesand fields produced 40 million barrels or only a fraction of the original oil in place, leaving behind significant recoverable reserves. Hunter Oil plans to unlock the value in these resource-rich fields by leveraging existing infrastructure, lowering operating costs and increasing efficiencies of its operations. By exploiting the pre-existing infrastructure at these proven, legacy assets, Hunter Oil is poised to capitalize on a significantly reduced exploration and finding cost threshold that enables profitability. Net present value of its reserves in these fields, discounted at 10 percent, is estimated at US$829.7 million as disclosed in the company’s year-end 2017 reserve report(1).

The Company’s wholly-owned subsidiary, Ridgeway Arizona Oil Corp., recently received drilling permits for five wells in its Chaveroo oil field. Hunter Oil intends to develop the Chaveroo reserves by drilling up to 84 horizontal wells. These permits represent the first group of wells to be drilled in the planned program and mark a significant milestone. During the past three years, the Company has readied the two oil fields for their next phase of exploitation via infill horizontal redevelopment.

The planned wells will target the San Andres formation at approximately 4,500’ TVD (true vertical depth) and will be one-mile-long horizontal wells. The Chaveroo oil field has reserves targeted for exploitation of 22 MMBOE (million barrels of oil equivalent) consisting of Proved Undeveloped reserves of 8.4 MMBOE, Probable reserves of 3.4 MMBOE, and Possible reserves of 10.2 MMBOE, as disclosed in the Company’s year-end 2017 reserve report(1).

Hunter Oil’s management team has decades of experience in oil production, both internationally and domestically, allowing for a greater understanding of operating assets on both state and federally regulated lands. Al H. Denson, P.E., recently appointed as Chief Executive Officer of Hunter Oil Corp., is an active member of the Society of Petroleum Engineers with more than 40 years of exploration and production experience. He began his career in 1976 with Amoco Corporation (now BP), where he served in various engineering, operational and management roles, both in the U.S. and internationally. Mr. Denson, who served as a director and member of the Company’s Operating Committee from 2014 to 2017, earned both a Bachelor’s degree and Master’s degree in Petroleum Engineering from Mississippi State University and is a Registered Professional Engineer in the State of Louisiana.

As a believer in corporate responsibility, Hunter Oil is committed to safe and responsible exploration and development practices that reflect a thoughtful awareness of the impact its operations have on the environment and community. Hunter Oil’s mission is to bring environmental, social and economic value to all of its stakeholders.

(1) This information is a summary only and readers are referred to the Company’s news release dated April 26, 2018 for further details, as well as to the evaluation of the Company’s reserves conducted by independent qualified reserves evaluator, Cawley, Gillespie & Associates, Inc., effective December 31, 2017 which is available at

Hunter Oil Corp. (HOILF), closed the day's trading session at $0.9926, even for the day. The average volume for the last 60 days is 4,277 and the stock's 52-week low/high is $0.2533/$2.02.

Recent News


Zenergy Brands, Inc. (OTC: ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

The global press toward finding technology-based advances that are more environmentally friendly, energy-efficient and “smart” is reflected in a variety of industries. Zenergy Brands, Inc. (OTC: ZNGY) is lending its resources and experience to those efforts in the utilities use sector.

Zenergy Brands, Inc. (OTC: ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.001485, up 5.32%, on 17,120,631 volume with 37 trades. The average volume for the last 60 days is 8,731,777 and the stock's 52-week low/high is $0.0014/$0.032.

Recent News


Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile (TSX.V: LITH) (OTCQB: LTMCF) holds the largest privately-owned lithium claims in Chile, with properties ranging over 152,900 hectares. To view the full article, visit:

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.80, up 9.98%, on 231,352 volume with 89 trades. The average volume for the last 60 days is 31,175 and the stock's 52-week low/high is $0.5692/$0.9614.

Recent News


Pivot Pharmaceuticals Inc. (OTCQB: PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

Pivot Pharmaceuticals’ (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) patented Ready To Infuse Cannabis (“RTIC”) powder is drawing the attention of respected cannabis brands in California, resulting in potential manufacturing and supply agreements for the company. To view the full article, visit:

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.40, up 4.52%, on 6,767 volume with 15 trades. The average volume for the last 60 days is 135,249 and the stock's 52-week low/high is $0.047/$2.46.

Recent News


Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a rising cannabis producer that is gaining a solid foothold in the consumer-populated markets of California and Canada, has announced the close of its 126-acre site in British Columbia’s rural Okanagan Falls-Similkameen district located 45 kilometers (28 miles) north of the U.S.-Canada border.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.3591, up 3.42%, on 61,085 volume with 80 trades. The average volume for the last 60 days is 36,536 and the stock's 52-week low/high is $5.7358/$16.00.

Recent News


The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) (the “Company” or “TGOD”) reports the resignation of CEO, Co-Chairman & Director, Mr. Robert Anderson, effective immediately, due to health concerns.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $6.48, up 1.09%, on 647,340 volume. The stock's 52-week low/high is $3.50/$8.28.

Recent News



The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO Inc. (OTCQB: EVIO) ("EVIO" or the "Company"), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce it has filed and obtained a receipt for its preliminary non-offering prospectus ("Preliminary Prospectus") with the Ontario Securities Commission (the "OSC").

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.09, even for the day, on 118,085 volume with 143 trades. The average volume for the last 60 days is 101,180 and the stock's 52-week low/high is $0.47/$2.70.

Recent News


Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Over the past couple months, Net Element, Inc. (NASDAQ: NETE) has increased its portfolio of payment solutions aimed at both huge markets and underrepresented market segments. The global technology and value-added solutions provider focuses on electronic payment acceptance in multi-channel environments.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.554, up 2.78%, on 58,310 volume with 276 trades. The average volume for the last 60 days is 346,208 and the stock's 52-week low/high is $2.556/$33.51.

Recent News


Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

Mineral exploration company Marifil Mines (TSX.V: MFM) (OTCQB: MFMLF) is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. To view the full article, visit:

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.1204, even for the day. The average volume for the last 60 days is 1,934 and the stock's 52-week low/high is $0.01/$0.165.

Recent News


Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

NetworkNewsAudio announces the Audio Press Release (APR) titled "Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used," featuring Virtual Crypto Technologies Inc. (OTCQB: VRCP). To hear the NetworkNewsAudio version, visit: To read the original editorial, visit:

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website,, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

  • Downloadable NetoBit Trader app link and contact forms for more information
  • MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
  • Improved security utilizing https certificates to protect personal information and site integrity
  • Media room with downloadable product brochures, corporate presentations and other relevant content
  • Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
  • Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.14, off by 6.04%, on 29,762 volume with 18 trades. The average volume for the last 60 days is 37,865 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News


Hammer Fiber Optic Holdings Corp. (OTCQB: HMMR)

The QualityStocks Daily Newsletter would like to spotlight Hammer Fiber Optic Holdings Corp. (HMMR).

The broadcasting of “NEW TO THE STREET” business TV show will be July 23, 24 & 25, 2018 @11:00 PM PDT on Fox Business Network. The Show’s new content, filmed in studio on June 28, 2018, features for the first time Hammer Fiber Optic (OTCQB:HMMR).

Hammer Fiber Optic Holdings Corp. (HMMR), with headquarters in New Jersey, is a telecommunications company investing in the future of wireless technology. The company’s holdings include Hammer Fiber Optic Investments, Ltd., D/B/A Hammer Fiber, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology.

Hammer Fiber recently completed the initial development phase of its advanced LTE fixed wireless system, which was designed and built upon its successfully deployed wireless technology suite. The expansion allows Hammer Fiber to add ultra-high capacity cellular broadband applications to its product portfolio including wholesale services such as backhaul support for cellular network operators. Designed to complement Hammer Fiber’s core business of home residential service, the company expects this latest innovation to help position Hammer Fiber as a leader in future 5G technology. The company intends to leverage the Fixed LTE system in conjunction with its already deployed Fixed Wireless DOCSIS 3.1 system to deliver on one of its core promises, to deliver high capacity broadband to markets across the country at dramatically lower cost than traditional wireline methods, including fiber. Live field testing of the new system begins in early 2018 in the U.S. with service availability to follow later in the year.

Hammer Fiber has also expanded its IaaS (Infrastructure-as-a-Service) cloud services to include support for the cryptocurrency and blockchain industry. Interested companies will be able to host their products over Hammer Fiber’s robust and modern server infrastructure, fiber network architecture and data center presence in some of the most secure locations in the New York, New Jersey and Philadelphia regions. Hammer Fiber’s servers feature best-in-class computing power, designed to allow enterprise businesses to reap the benefits of utilizing a cloud-based system without the massive cost of establishing or maintaining a corporate data center.

“Distributed architecture infrastructure, such as those utilized by blockchain entities mining cryptocurrencies or other new vertical markets utilizing blockchain technology, are growing exponentially and we are poised to fulfill a critical but fundamental need of this explosive new industry,” said Mark Stogdill, CEO of Hammer Fiber. “The distributed ledger architectures that blockchains are built on require secure and robust data processing networks, highly scalable power generation and a reliable fiber optic backbone infrastructure linking up data centers worldwide for them to exist, and that is what we at Hammer Fiber do really well.”

Hammer Fiber seeks to achieve its vision by employing an extremely qualified group of business professionals with diverse backgrounds and successful track records from a variety of related industries. HMMR’s seasoned leadership team combines startup expertise with a consummate understanding of the regional competitive telecommunications landscape in sales, marketing, engineering, construction and business development.

Hammer Fiber Optic Holdings Corp. (HMMR), closed the day's trading session at $1.01, off by 4.81%, on 88,332 volume with 137 trades. The average volume for the last 60 days is 88,688 and the stock's 52-week low/high is $0.882/$48.00.

Recent News


Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

A rising demand for advanced driver safety and assistance systems that help drivers control vehicles and avoid accidents is fueling a global market for technological innovations in an increasingly high growth market, according to multiple industry research reports. Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), a technological innovator in automotive vision systems and driver assistance technology headquartered in Israel, has been developing, through wholly owned subsidiary Foresight Automotive Ltd., a powerful and mature proprietary stereoscopic technology that provides real-time information to prevent accidents.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $3.4848, off by 4.06%, on 99,298 volume with 237 trades. The average volume for the last 60 days is 53,493 and the stock's 52-week low/high is $2.44/$10.45.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.